What it's for (Indications)
- This combination medication, comprising beclomethasone dipropionate and formoterol fumarate, is primarily indicated for the regular maintenance treatment of asthma in adults and adolescents (12 years and older) where the use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate.
- This includes patients not adequately controlled with inhaled corticosteroids and 'as-needed' short-acting beta2-agonists, or patients whose disease severity warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta2-agonist.
- It is also indicated for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) in adults with a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.
- It is crucial to understand that this medication is not intended for the relief of acute bronchospasm, and patients should have a rescue inhaler readily available for such events.
- The use is strictly for maintenance therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for beclomethasone/formoterol must be individualized and adjusted according to the severity of the patient's disease and their response to treatment, always under the guidance of a healthcare professional. For asthma, the typical maintenance dose for adults and adolescents (12 years and older) is usually one or two inhalations twice daily, depending on the specific strength of the product (e.g., 100/6 mcg or 200/6 mcg, where the first number indicates beclomethasone and the second indicates formoterol). For chronic obstructive pulmonary disease (COPD), the recommended dosage for adults is typically two inhalations of the lower strength product (e.g., 100/6 mcg) twice daily. Patients should be regularly reassessed by a healthcare professional to ensure that the dosage remains optimal and to consider stepping down therapy if asthma control is well-maintained. The medication must be inhaled orally using the prescribed device, and proper inhalation technique is paramount for efficacy. Patients should be instructed to rinse their mouth thoroughly with water after each use to minimize the risk of oral candidiasis (thrush). |
Safety & Warnings
Common Side Effects
- Patients utilizing beclomethasone/formoterol may experience various side effects, which can range in severity and frequency.
- Common side effects often include oral candidiasis (thrush) and dysphonia (hoarseness) due to the corticosteroid component, as well as headache, throat irritation, tremor, and palpitations, which can be attributed to the beta2-agonist component.
- Less common but notable adverse reactions can include insomnia, dizziness, anxiety, muscle cramps, tachycardia, and hyperglycemia.
- More serious adverse effects, though less frequent, may encompass paradoxical bronchospasm, an acute, life-threatening reaction characterized by immediate worsening of breathing after inhalation; systemic corticosteroid effects such as adrenal suppression, reduction in bone mineral density (osteoporosis risk), cataracts, and glaucoma, especially with prolonged high-dose use; and cardiovascular effects like angina or cardiac arrhythmias.
- Immunosuppression leading to an increased susceptibility to infections is also a concern.
- Any signs of a severe allergic reaction (e.
- g.
- , angioedema, urticaria, rash) or significant worsening of respiratory symptoms warrant immediate medical evaluation.
Serious Warnings
- Black Box Warning: **Long-Acting Beta2-Adrenergic Agonists (LABA) - Asthma-Related Death** LABA monotherapy increases the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial (SMART study) showed that LABAs increased the risk of asthma-related deaths. Therefore, for patients with asthma, beclomethasone/formoterol should only be used for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and, if appropriate, step down therapy (e.g., discontinue beclomethasone/formoterol) while maintaining good asthma control with an inhaled corticosteroid. This product should not be used for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids. Beclomethasone/formoterol is not indicated for the primary treatment of acute episodes of bronchospasm or for acute exacerbations of asthma or COPD. The safety and efficacy of LABAs, including formoterol, as monotherapy for asthma have not been established, and their use without an inhaled corticosteroid in asthma is generally not recommended due to this increased risk.
- This medication is strictly for maintenance treatment and is not to be used for the rapid relief of acute symptoms of asthma or COPD.
- Patients must be advised to carry a short-acting beta2-agonist (rescue inhaler) for acute episodes.
- Abrupt discontinuation of beclomethasone/formoterol, particularly in patients previously on higher doses of systemic corticosteroids, may precipitate adrenal insufficiency; therefore, withdrawal should be gradual and under medical supervision.
- Due to the formoterol component, caution is warranted in patients with cardiovascular disorders (e.
- g.
- , cardiac arrhythmias, hypertension, coronary insufficiency), convulsive disorders, thyrotoxicosis, or diabetes mellitus, as it may exacerbate these conditions.
- The corticosteroid component may lead to systemic effects, especially at high doses or during prolonged treatment, including adrenal suppression, reductions in bone mineral density, and ocular effects like glaucoma and cataracts.
- Patients with COPD using inhaled corticosteroids may have an increased risk of pneumonia; clinicians should remain vigilant for signs of lower respiratory tract infection.
- Regular monitoring for signs of infection and potential immunosuppression is also important.
- This combination product is not recommended for pediatric patients under 12 years of age for asthma treatment due to insufficient safety and efficacy data in this population.
How it Works (Mechanism of Action)
Beclomethasone/formoterol combines two distinct pharmacological agents to provide comprehensive management of inflammatory airway diseases. Beclomethasone dipropionate is an inhaled corticosteroid (ICS) that acts locally within the airways. It functions as a potent anti-inflammatory agent by binding to glucocorticoid receptors, which in turn modulates gene expression to reduce the synthesis and release of inflammatory mediators (e.g., cytokines, chemokines) and suppress immune cell activity (e.g., eosinophils, mast cells, lymphocytes). This action decreases airway hyperresponsiveness, reduces mucus production, and lessens airway edema, ultimately improving lung function and reducing the frequency and severity of asthma exacerbations. Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA). It selectively stimulates beta2-adrenergic receptors found predominantly on airway smooth muscle cells. This stimulation activates adenyl cyclase, leading to an increase in intracellular cyclic AMP, which in turn causes relaxation of bronchial smooth muscle and subsequent bronchodilation. The prolonged action of formoterol provides sustained airway opening. The synergistic combination of an ICS and a LABA effectively addresses both the underlying inflammatory process and the bronchoconstriction characteristic of asthma and COPD, offering sustained symptom control and contributing to a reduction in exacerbations.